Argenx Se (ARGX) Goodwill & Intangibles (2015 - 2026)
Argenx Se's (ARGX) quarterly Goodwill & Intangibles came in at $266.0 million in Q2 2026, down 99.92% YoY from $352.3 billion in Q2 2025, and down 35.21% on a QoQ basis from $410.6 million in Q4 2025.
Argenx Se (ARGX) Goodwill & Intangibles (2015 - 2026) Analysis & Trends
Argenx Se (ARGX) has 12 years of Goodwill & Intangibles data on file, last reported at $266.0 million in Q2 2026.
- Quarterly Goodwill & Intangibles fell 99.92% year-over-year to $266.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $266.0 million (down 99.92% YoY) and the FY2025 annual result came in at $7.5 billion, up 22.81% from the prior year.
- Goodwill & Intangibles eased to $266.0 million in Q2 2026, from $410.6 million in the prior quarter.
- In the past five years, Goodwill & Intangibles ranged from a high of $352.3 billion in Q2 2025 to a low of $256.8 million in Q4 2023.
- A 5-year average of $39.4 billion and a median of $305.8 million in 2022 frame the typical range for Goodwill & Intangibles.
- Annual changes were most pronounced in 2025 — Goodwill & Intangibles surged 130048.98% — and 2026, when it plunged 99.92%.
- Tracing ARGX's Goodwill & Intangibles over 5 years: stood at $305.8 million in 2022, then decreased by 16.03% to $256.8 million in 2023, then grew by 20.06% to $308.3 million in 2024, then jumped by 33.18% to $410.6 million in 2025, then slumped by 35.21% to $266.0 million in 2026.
- The last three Goodwill & Intangibles figures came in at $266.0 million (Q2 2026), $410.6 million (Q4 2025), and $352.3 billion (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 266.00 Mn |
| Dec 31, 2025 | 410.57 Mn |
| Jun 30, 2025 | 352.33 Bn |
| Dec 31, 2024 | 308.28 Mn |
| Jun 30, 2024 | 270.71 Mn |
| Dec 31, 2023 | 256.77 Mn |
| Jun 30, 2023 | 319.90 Mn |
| Dec 31, 2022 | 305.80 Mn |
| Jun 30, 2022 | 299.99 Mn |
| Dec 31, 2021 | 303.37 Mn |
| Jun 30, 2021 | 308.33 Mn |
| Dec 31, 2020 | 162.64 Mn |
| Jun 30, 2020 | 45.10 Mn |
| Dec 31, 2019 | 44.45 Mn |
| Jun 30, 2019 | 39.86 Mn |
| Dec 31, 2018 | 63,918.20 |
| Jun 30, 2018 | 9,547.56 |
| Dec 31, 2017 | 116,565.82 |
| Jun 30, 2017 | 13,194.59 |
| Dec 31, 2016 | 18,355.31 |